Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ursula Maria Schmidt-Ott

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Current Heart Failure Reports|August 18, 2006
Thyroid hormone and heart failureUrsula Maria Schmidt-Ott, Deborah Davis Ascheim
Pharmaceutical Medicine|January 15, 2020
Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept in Europe: Evaluation of Risk-Minimization MeasuresLaurie J Zografos, Elizabeth Andrews, Daniel L Wolin, et al.
Pharmaceutical Medicine|December 4, 2023
Evaluation of Physician Knowledge of Safety and Safe Use Information for Intravitreal Aflibercept Injection in Europe: A Second Survey of Physicians Following Dissemination of Updated Risk-Minimization MaterialsLaurie J Zografos, Elizabeth Andrews, Dan L Wolin, et al.
International Journal of Retina and Vitreous|June 26, 2026
Intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration from China: 48-week results from the PULSAR trialXiaodong Sun, Hong Dai, Youxin Chen, et al.
Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa.)|January 10, 2026
Intravitreal aflibercept 8 mg versus 2 mg in Asian patients with neovascular age-related macular degeneration: 48-week analysis of the Phase 3 PULSAR trialAndrew Chang, Xiaodong Sun, Tomohiro Iida, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Current Heart Failure Reports|August 18, 2006
Thyroid hormone and heart failureUrsula Maria Schmidt-Ott, Deborah Davis Ascheim
Pharmaceutical Medicine|January 15, 2020
Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept in Europe: Evaluation of Risk-Minimization MeasuresLaurie J Zografos, Elizabeth Andrews, Daniel L Wolin, et al.
Pharmaceutical Medicine|December 4, 2023
Evaluation of Physician Knowledge of Safety and Safe Use Information for Intravitreal Aflibercept Injection in Europe: A Second Survey of Physicians Following Dissemination of Updated Risk-Minimization MaterialsLaurie J Zografos, Elizabeth Andrews, Dan L Wolin, et al.
International Journal of Retina and Vitreous|June 26, 2026
Intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration from China: 48-week results from the PULSAR trialXiaodong Sun, Hong Dai, Youxin Chen, et al.
Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa.)|January 10, 2026
Intravitreal aflibercept 8 mg versus 2 mg in Asian patients with neovascular age-related macular degeneration: 48-week analysis of the Phase 3 PULSAR trialAndrew Chang, Xiaodong Sun, Tomohiro Iida, et al.
Pageof 1